Lisa L. Liu
Stockholm, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma.
Journal: Expert review of anticancer therapy
Published: January 12, 2026
Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab.
Journal: Acta oncologica (Stockholm, Sweden)
Published: August 03, 2025
Evaluation of the flipped dose NIVO3+IPI1 in patients with advanced unresectable melanoma.
Journal: Journal of the National Cancer Institute
Published: July 24, 2025
Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden.
Journal: Oncoimmunology
Published: July 08, 2024
Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.
Journal: Journal for immunotherapy of cancer
Published: January 17, 2023
Renal cell carcinoma escapes NK cell-mediated immune surveillance through the downregulation of DNAM-1.
Journal: Cancer communications (London, England)
Published: November 21, 2022
Clinical characteristics and factors associated with COVID-19-related death and morbidity among hospitalized patients with cancer: a Swedish cohort study.
Journal: Acta oncologica (Stockholm, Sweden)
Published: August 02, 2021
Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25+ /CD54+ NK cells.
Journal: EMBO reports
Published: July 15, 2020
Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors.
Journal: Cancers
Published: May 29, 2019
Remodeling of secretory lysosomes during education tunes functional potential in NK cells.
Journal: Nature communications
Published: July 09, 2018
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 29, 2017
Last Updated: 09/26/2026